Applied Genetic Technologies Corporation (AGTC)
AGTC Price and Sentiment
AGTC Latest news
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
2021-10-19 08:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.
AGTC Announces Two Key Leadership Team Appointments
2021-10-14 17:00- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
2021-10-12 11:08GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021.
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
2021-09-27 08:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
2021-09-24 09:59After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems. The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a.
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
2021-09-23 22:38Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
2021-09-23 16:05-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-
AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
2021-09-16 08:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update.
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 10:23GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th, 2021.
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
2021-09-02 09:41GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference on September 10th, 2021 at 8:40am E.T.